omega-3 ethylester concentrate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 171 Diseases   26 Trials   26 Trials   2439 News 


12345678910111213...2021»
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery (clinicaltrials.gov) -  Apr 10, 2025   
    P2,  N=90, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2027 --> Oct 2027 Trial completion date: Nov 2025 --> Feb 2027 | Initiation date: Nov 2024 --> Aug 2025 | Trial primary completion date: Nov 2025 --> Aug 2026
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion, Trial completion date:  EMiRA: The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation (clinicaltrials.gov) -  Apr 3, 2025   
    P3,  N=174, Completed, 
    Trial completion date: Nov 2025 --> Feb 2027 | Initiation date: Nov 2024 --> Aug 2025 | Trial primary completion date: Nov 2025 --> Aug 2026 Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Mar 2025
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (clinicaltrials.gov) -  Mar 11, 2025   
    P2,  N=75, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Mar 2025 Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2025 --> Aug 2025
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (clinicaltrials.gov) -  Nov 27, 2024   
    P2,  N=75, Recruiting, 
    While most beneficiaries received generic medications when available, substantial spending on brand-name medications persists, indicating potential missed opportunities for cost savings. Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (clinicaltrials.gov) -  Jul 30, 2024   
    P=N/A,  N=40, Active, not recruiting, 
    The study results may contribute to the development of future treatment strategies for patients with MASLD/MASH. Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Nov 2024 --> Nov 2026
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery (clinicaltrials.gov) -  Jul 24, 2024   
    P2,  N=90, Not yet recruiting, 
    Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Nov 2024 --> Nov 2026 Trial completion date: Jun 2025 --> Nov 2025 | Initiation date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2025 --> Nov 2025
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Retrospective data, Review, Journal:  Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis. (Pubmed Central) -  Jul 23, 2024   
    It is important to note that omega-3 fatty acids should be applied with caution in patients with previous myocardial infarction, which may increase the risk of stroke. Finally, omega-3 fatty acids are relatively safe and in general do not increase gastrointestinal problems, bleeding-related disorders, or cancer, but attention needs to be paid to the risk of bleeding with prescription EPA ethyl ester formulations.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Journal:  Reversed-Phase Medium-Pressure Liquid Chromatography Purification of Omega-3 Fatty Acid Ethyl Esters Using AQ-C18. (Pubmed Central) -  Jun 26, 2024   
    In contrast, RP-MPLC significantly enhanced the production efficiency per unit output compared to RP-HPLC. This study demonstrates a pioneering approach to producing omega-3 fatty acid ethyl esters with high purity and of greater quantity using AQ-C18 RP-MPLC, showing this method's significant potential for use in industrial-scale manufacturing.
  • ||||||||||  atorvastatin / Generic mfg., atorvastatin/fenofibrate / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
    Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome (Kiosk 22) -  Jun 12, 2024 - Abstract #NLA2024NLA_188;    
    Plasmapheresis, though costly and invasive, offers a rapid reduction in TG, symptom resolution, and prevention of HTG-associated complications. Future studies on these treatment modalities can aid in developing inpatient management guidelines for chylomicronemia syndrome.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion:  Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia (clinicaltrials.gov) -  May 8, 2024   
    P4,  N=32, Completed, 
    N=173 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Unknown status --> Completed
  • ||||||||||  niacin extended-release formulation / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
    Journal:  Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome. (Pubmed Central) -  Mar 1, 2024   
    However the combination had no statistically significant effect, 10% (-9, 31 CI, P = 0.39). With regard to P-OM3 therapy in particular, the HAE assay detected an increase in this property in the absence of a concomitant rise in HDL-C and apoA-I levels, suggesting that the assay can detect functional changes in HDL that occur in the absence of traditional biomarkers.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Journal:  Safety update: omega-3-acid ethyl esters and atrial fibrillation. (Pubmed Central) -  Mar 1, 2024   
    Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000 mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors. Drug Safety Update 2024;17(6):3.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  ALTA: Altering Lipids for Tolerance of Aromatase Inhibitor Therapy (clinicaltrials.gov) -  Nov 27, 2023   
    P2,  N=77, Active, not recruiting, 
    The promise of optimized patient compliance and reduced dosages adds further weight to its potential significance. Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Dec 2023
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (clinicaltrials.gov) -  Sep 22, 2023   
    P2,  N=75, Recruiting, 
    The results of this pilot study do not support further study of the use of omega-3 fatty acids for the prevention of the P-APS and CIPN. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion:  ALTA: Altering Lipids for Tolerance of Aromatase Inhibitor Therapy (clinicaltrials.gov) -  Aug 31, 2023   
    P2,  N=77, Completed, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  VITAL: Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes (clinicaltrials.gov) -  May 31, 2023   
    P=N/A,  N=25875, Active, not recruiting, 
    Trial primary completion date: Apr 2023 --> Jun 2022 Trial completion date: Oct 2021 --> May 2024 | Trial primary completion date: Oct 2021 --> May 2024
  • ||||||||||  atorvastatin / Generic mfg., spironolactone / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
    The Aftermath of Pueraria mirifica: A Case of Hypertriglyceridemia and Necrotizing Pancreatitis in a Non-binary Individual with Surreptitious Use of Oral Estrogenic Compounds (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2451;    
    Patient discharged on fenofibrate 200 mg, atorvastatin 20 mg and omega-3 acid ethyl esters 2 g BID, with plan for endocrinology follow-up for initiation of medically supervised GAHT.At follow-up on this regimen, LDL was 79 mg/dL and triglycerides 160 mg/dL...Given patient's desire for partial transition, low dose transdermal estradiol 0.05 mg patch and spironolactone 50mg BID started...It also illustrates how distrust of the medical system led to surreptitious hormone use and emphasizes the need to create a safe, welcoming environment for individuals with gender dysphoria. Finally, it emphasizes the need to interrogate possible surreptitious hormone use in patients with unusual presentations and for endocrinologists to be aware of the need to avoid oral estrogen use in patients with hypertriglyceridemia.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Phase classification:  Bioavailability of EPA + DHA in a SMEDS Formulation (clinicaltrials.gov) -  Mar 23, 2023   
    P=N/A,  N=24, Completed, 
    Further large-scale and long-term studies, including evaluation of liver histology, are expected in the future. Phase classification: P4 --> P=N/A
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Enrollment change, Trial termination:  Immunonutrition for Diabetic Foot Ulcers (clinicaltrials.gov) -  Mar 22, 2023   
    P2/3,  N=1, Terminated, 
    Phase classification: P4 --> P=N/A N=30 --> 1 | Enrolling by invitation --> Terminated; There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Preclinical, Journal:  Cardiovascular and lipid-lowering effects of a marine lipoprotein extract in a high-fat diet-induced obesity mouse model. (Pubmed Central) -  Mar 3, 2023   
    Regular consumption of dark-meat fish is linked to a lower incidence of CVD and associated metabolic disorders due to the presence of long-chain omega-3 fatty acid ethyl esters in fish oils...Our data show that RCI-1502 is beneficial for reducing obesity associated with a long-term HFD, possibly by exerting a protective effect on lipidic homeostasis, indicated also by histopathological analysis. These results collectively indicate that RCI-1502 acts as a cardiovascular therapeutic nutraceutical agent, which modulates fat-induced inflammation and improves metabolic health.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Biomarker, Trial primary completion date:  Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (clinicaltrials.gov) -  Jan 18, 2023   
    P2,  N=75, Recruiting, 
    This 3-year prospective post-marketing surveillance study evaluated the effect of omega-3-acid ethyl esters (O3AEE; usual dosage 2 Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial initiation date:  Immunonutrition for Diabetic Foot Ulcers (clinicaltrials.gov) -  Dec 22, 2022   
    P2/3,  N=30, Enrolling by invitation, 
    Trial primary completion date: Dec 2022 --> Dec 2023 Initiation date: Oct 2022 --> Jul 2022